Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Elisa Tassinari
Observed names:
E. Tassinari,
Tassinari, Elisa
Institution:
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
Observed institutions:
IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola,
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori,
University of Bologna
ORCID:
0000-0002-3457-0760
Observed ORCID:
0000-0002-3457-0760
OpenAlex ID:
A5058312668
The impact of ECOG performance status on efficacy of immunotherapy and immune-based combinations in cancer patients: the MOUSEION-06 study
2023
·
Veronica Mollica
, Alessandro Rizzo
, et al.
·
Clinical and Experimental Medicine
·
168
Hypertransaminasemia in cancer patients receiving immunotherapy and immune-based combinations: the MOUSEION-05 study
2023
·
Alessandro Rizzo
, Veronica Mollica
, et al.
·
Cancer Immunology Immunotherapy
·
161
PDF
Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis
2023
·
Matteo Santoni
, Alessandro Rizzo
, et al.
·
Cancer Immunology Immunotherapy
·
151
PDF
The Molecular Characteristics of Non-Clear Cell Renal Cell Carcinoma: What’s the Story Morning Glory?
2021
·
Andrea Marchetti
, Matteo Rosellini
, et al.
·
International Journal of Molecular Sciences
·
36
PDF
Adjuvant PD-1 and PD-L1 Inhibitors and Relapse-Free Survival in Cancer Patients: The MOUSEION-04 Study
2022
·
Alessandro Rizzo
, Veronica Mollica
, et al.
·
Cancers
·
34
PDF
PARP Inhibitors and Radiometabolic Approaches in Metastatic Castration-Resistant Prostate Cancer: What’s Now, What’s New, and What’s Coming?
2022
·
Andrea Marchetti
, Matteo Rosellini
, et al.
·
Cancers
·
21
PDF
Bone Targeting Agents in Patients with Prostate Cancer: General Toxicities and Osteonecrosis of the Jaw
2022
·
Veronica Mollica
, Giacomo Nuvola
, et al.
·
Current Oncology
·
17
PDF
State of the art of adjuvant immunotherapy in urothelial cancer: New developments and upcoming changes
2024
·
Elisa Tassinari
, Linda Danielli
, et al.
·
Human Vaccines & Immunotherapeutics
·
16
Novel Immune Checkpoint Inhibitor Targets in Advanced or Metastatic Renal Cell Carcinoma: State of the Art and Future Perspectives
2024
·
Samuele Compagno
, Chiara Casadio
, et al.
·
Journal of Clinical Medicine
·
15
PDF
From Monoamine Oxidase Inhibition to Antiproliferative Activity: New Biological Perspectives for Polyamine Analogs
2023
·
Giulia Nordio
, Francesco Piazzola
, et al.
·
Molecules
·
13
PDF
Treatment Options for Metastatic Urothelial Carcinoma After First-Line Chemotherapy
2022
·
Elisa Tassinari
, Veronica Mollica
, et al.
·
Cancer Management and Research
·
12
PDF
Prognostic Factors of Survival for High-Grade Neuroendocrine Neoplasia of the Bladder: A SEER Database Analysis
2022
·
Veronica Mollica
, Francesco Massari
, et al.
·
Current Oncology
·
11
PDF
Implications of TERT promoter mutations and telomerase activity in solid tumors with a focus on genitourinary cancers
2022
·
Paola Valeria Marchese
, Veronica Mollica
, et al.
·
Expert Review of Molecular Diagnostics
·
10
First in Class Dual Non-ATP-Competitive Glycogen Synthase Kinase 3β/Histone Deacetylase Inhibitors as a Potential Therapeutic to Treat Alzheimer’s Disease
2024
·
Alan Santini
, Elisa Tassinari
, et al.
·
ACS Chemical Neuroscience
·
9
An update on safety evaluation of immune-based combinations in patients with advanced renal cell carcinoma
2023
·
Matteo Rosellini
, Elisa Tassinari
, et al.
·
Expert Opinion on Drug Safety
·
9
Prostate cancer and novel pharmacological treatment options–what’s new for 2022?
2023
·
Andrea Marchetti
, Elisa Tassinari
, et al.
·
Expert Review of Clinical Pharmacology
·
9
The Palliative Prognostic (PaP) Score without Clinical Evaluation Predicts Early Mortality among Advanced NSCLC Patients Treated with Immunotherapy
2022
·
Andrea De Giglio
, Elisa Tassinari
, et al.
·
Cancers
·
9
PDF
Immune-based Combinations in Intermediate-/Poor-risk Patients with Non–clear Cell Renal Cell Carcinoma: Results from the ARON-1 Study
2025
·
Francesco Massari
, Veronica Mollica
, et al.
·
European Urology Focus
·
7
Pathological and Clinical Implications of Tumor Microenvironment Evaluated With Multiplex Immunohistochemistry in Testicular Embryonal Carcinoma
2025
·
Valentina Tateo
, Costantino Ricci
, et al.
·
Clinical Genitourinary Cancer
·
6
Current androgen receptor antagonists under investigation for resistant prostate cancer: progress and challenges
2025
·
Linda Danielli
, Elisa Tassinari
, et al.
·
Expert Review of Anticancer Therapy
·
6
How Do Molecular Classifications Affect the Neoadjuvant Treatment of Muscle-Invasive Urothelial Carcinoma?
2023
·
Nicole Conci
, Elisa Tassinari
, et al.
·
Molecular Diagnosis & Therapy
·
6
Neuroendocrine prostate cancer (NEPC) in focus: state of the art and future prospectives
2026
·
Emilio Francesco Giunta
, Giuseppe Schepisi
, et al.
·
Discover Oncology
·
5
AR-A014418-based dual Glycogen Synthase Kinase 3β/Histone Deacetylase inhibitors as potential therapeutics for Alzheimer's disease
2025
·
Alan Santini
, Elisa Tassinari
, et al.
·
European Journal of Medicinal Chemistry
·
5
Leveraging targeted kinase degradation as a novel therapeutic strategy for Alzheimer's disease
2025
·
Elisa Tassinari
, Andrea Milelli
·
RSC Medicinal Chemistry
·
5
PDF
Chromosome 3p gene alterations as biomarkers for immunocombinations in metastatic renal cell carcinoma: A hypothesis-generating analysis
2024
·
Matteo Rosellini
, Veronica Mollica
, et al.
·
Pathology - Research and Practice
·
5
Show more works
View as search
Works count:
46
Citation count:
793
H-index:
11
I10-index:
13
Year
Topic
Type